Changes in the bioprocessing market demand new ways of thinking. The industry needs smart solutions for easily scaling up or down production. Financial and production risks must also be minimized while adhering to strict demands from regulating bodies.
Cytiva, provides bioprocessing products and services to the biopharmaceutical industry for the development and manufacture of therapeutics and vaccines.
The company uses its scientific knowledge and technical expertise to help biomanufacturers increase speed-to-market, reduce costs, and improve productivity.
Single-use solutions for bioprocessing
The company provides a wide range of innovative single-use solutions designed to achieve high productivity. Ranging from single-use workflows and biomanufacturing facilities to disposable chromatography columns, the company’s offerings help drive collaboration in the pharmaceutical industry.
Upstream and downstream bioprocessing
Cytiva provides a wide range of integrated products and solutions to meet the needs of the biopharmaceutical industry for upstream and downstream bioprocessing.
Cytiva (formerly GE Life Sciences)
Its portfolio includes products for cell culture and fermentation (HyClone™ cell culture media, sera, process liquids, ReadyToProcess WAVE™, Xcellerex™ bioreactors and Xcellerex fermentors), chromatography (ÄKTA™ chromatography system, chromatography columns and resins, and in-line conditioning systems), filtration (tangential flow filtration and ULTA™ normal flow filtration products), and liquid preparation and management (Xcellerex single-use mixers, ReadyKart™ mobile processing stations, ReadyToProcess™ storage bins and assemblies, and ReadyCircuit™ bag assemblies and ReadyMate™ connectors).
Cytiva also offers single-use systems, components, assemblies, and manufacturing facility solutions.
Biomanufacturing design and management for therapies and vaccines
Cytiva offers drug developers an array of biomanufacturing solutions that increase efficiency and optimize productivity. GE’s Enterprise Solutions provide an end-to-end platform for biologics management with innovative, modular solutions for the launch of new molecules, bringing biosimilars to an emerging market, or expanding biomanufacturing capacity to support production needs. Enterprise Solutions provides clients with new options to achieve their biomanufacturing goals.
FlexFactory™ is an integrated, single-use, or hybrid biomanufacturing platform that provides rapid access to current good manufacturing practice (cGMP) manufacturing capacity while providing flexibility.
The KuBio™ facilities and BioPark campus each offer a configurable design space to meet the client’s biomanufacturing needs. These turnkey facility solutions delay capital investment, reduce business risk, and improve speed-to-market.
Fast Trak biomanufacturing services
Cytiva provides a wide range of Fast Trak™ support services for drug development applications, including increasing existing capacity, launching a new molecule, and bringing biosimilars to market. The company helps manufacturers stay competitive and maintain high speed-to-market.
Performed with open collaboration and transparency, the company offers services to support cell culture medium development, upstream and downstream process development, clinical manufacturing, analytical development, quality control, and process transfer.
Cytiva’s Fast Trak portfolio supports quick development from molecule to market, ensuring market approval is reached in as short a time and as cost-effectively as possible. The company also accelerates outcomes, mitigates risks and conducts its processes with full transparency to meet its clients’ needs.
In addition, Cytiva offers education courses globally for practical, hands-on bioprocess training. Fast Trak courses are offered at nine locations worldwide, in addition to on-demand courses.
Bioprocess security of supply
Higher productivity, purity, and yield have been the driving forces when designing manufacturing processes for biopharmaceuticals.
The choices you make today will impact your manufacturing process for several years ahead.
For the development of an optimised process and for consistent and cost-effective biopharmaceutical production, a close collaboration between the manufacturer and its supplier is beneficial.
Cytiva offers products, services and support to assist you throughout your product’s lifecycle.
GE Healthcare knows that speed is important to you. That’s why it focuses on increasing productivity, optimizing protein quality and simplifying your operations right from the start.
GE Healthcare knows that rising titres upstream are a challenge downstream. That’s why the company is putting its more than 50 years’ downstream experience to work helping you to intensify your process and improve the economy, today and in the future.
What are the emerging trends and hot topics in biopharma, and how can companies take advantage of them in order to succeed?
When you partner with GE Healthcare’s Life Sciences you get access to a wide selection of high performance, customisable components and solutions for immunoassay and molecular diagnostic applications.
The biopharmaceutical industry has a reputation for being averse to change. This is likely because traditional approaches to drug development have withstood the test of time, delivering safe and effective drugs for decades.
This application note describes a broadly applicable and efficient workflow towards finding the optimal feed combination for best performing fed-batch processes.
Chinese biotechnology company Clover Biopharmaceuticals is planning to build a biomanufacturing facility in the Changxing Economic and Technological Development Zone (CETDZ) of Zhejiang, China.
Akeso Pharmaceuticals, a biotech company that focuses in the growth and commercialisation of innovative biologics, will open a facility in Guangzhou, China, based on GE Healthcare Life Sciences’ FlexFactory platform, intended for proficient and cost-effective production of recombinant biologics.
GE Healthcare (GEHC) and the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland are partnering to combine their expertise to deliver educational programming on biopharmaceutical and cell therapy development and manufacturing.
Visit GE Healthcare at booth #3141 to accelerate your bioprocess journey.
Since she was a child, Therése Kallur has been interested in how the mind works. Today, she makes spare parts for it.
The Swedish Government and GE Healthcare are opening Testa Center, an innovation centre in Uppsala, Sweden, to boost the commercialisation of new technologies and support manufacturing capabilities in the life sciences sector.
Clover Biopharmaceuticals has chosen GE Healthcare’s biomanufacturing platform FlexFactory for its new facility located in Changxing, Zhejiang, China.
United BioPharma (UBP) has selected GE Healthcare’s FlexFactory manufacturing platform for its new facility focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies in Hsinchu Industrial Park, Taiwan.
GE has completed a strategic minority investment in Irish-owned Zenith Technologies, a leading technology company delivering manufacturing software systems and solutions for the life sciences industry.
GE Healthcare Life Sciences has announced a $7m expansion project at its single-use technology manufacturing facility in Westborough, US.
GE Healthcare has announced that Dr. Reddy’s Laboratories will be installing India’s first-ever FlexFactory, a single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad, India.